Cargando…

The heterogeneity of cancer stem-like cells at the invasive front

Cancer stem-like cells exhibit the multi-functional roles to survive and persist for a long period in the minimal residual disease after the conventional anti-cancer treatments. Cancer stem-like cells of solid malignant tumors which highly express CD44v8-10, the variant isoform of CD44 generated by...

Descripción completa

Detalles Bibliográficos
Autor principal: Yoshida, Go J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307924/
https://www.ncbi.nlm.nih.gov/pubmed/28289330
http://dx.doi.org/10.1186/s12935-017-0393-y
_version_ 1782507462703710208
author Yoshida, Go J.
author_facet Yoshida, Go J.
author_sort Yoshida, Go J.
collection PubMed
description Cancer stem-like cells exhibit the multi-functional roles to survive and persist for a long period in the minimal residual disease after the conventional anti-cancer treatments. Cancer stem-like cells of solid malignant tumors which highly express CD44v8-10, the variant isoform of CD44 generated by alternative splicing, has a resistance to redox stress by the robust production of glutathione mediated by ESRP1-CD44v-xCT (cystine/glutamate antiporter) axis. It has been reported that CD44v and c-Myc tend to show the inversed expression pattern at the invasive front of the aggressive tumors. Given that the accumulation of reactive oxygen species triggers the activation of Wnt/β-catenin signal pathway, it is hypothesized that CD44v causes the negative feedback machinery in the regulation of c-Myc expression via the attenuated ROS-induced Wnt signal pathway. To address the fundamental question whether and how both proliferative and quiescent cancer stem-like cells heterogeneously exist at the invasive/metastatic edge, researchers need to investigate into the E3-ubiquitin ligase activity essential for c-Myc degradation. CSCs heterogeneity at the invasive/metastatic front is expected to demonstrate the dynamic tumor evolution with the selective pressure of anti-cancer treatments. Furthermore, the novel molecular targeting therapeutic strategies would be established to disrupt the finely-regulated c-Myc expression in the heterogeneous CSC population in combination with the typical drug-repositioning with xCT inhibitor.
format Online
Article
Text
id pubmed-5307924
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53079242017-03-13 The heterogeneity of cancer stem-like cells at the invasive front Yoshida, Go J. Cancer Cell Int Hypothesis Cancer stem-like cells exhibit the multi-functional roles to survive and persist for a long period in the minimal residual disease after the conventional anti-cancer treatments. Cancer stem-like cells of solid malignant tumors which highly express CD44v8-10, the variant isoform of CD44 generated by alternative splicing, has a resistance to redox stress by the robust production of glutathione mediated by ESRP1-CD44v-xCT (cystine/glutamate antiporter) axis. It has been reported that CD44v and c-Myc tend to show the inversed expression pattern at the invasive front of the aggressive tumors. Given that the accumulation of reactive oxygen species triggers the activation of Wnt/β-catenin signal pathway, it is hypothesized that CD44v causes the negative feedback machinery in the regulation of c-Myc expression via the attenuated ROS-induced Wnt signal pathway. To address the fundamental question whether and how both proliferative and quiescent cancer stem-like cells heterogeneously exist at the invasive/metastatic edge, researchers need to investigate into the E3-ubiquitin ligase activity essential for c-Myc degradation. CSCs heterogeneity at the invasive/metastatic front is expected to demonstrate the dynamic tumor evolution with the selective pressure of anti-cancer treatments. Furthermore, the novel molecular targeting therapeutic strategies would be established to disrupt the finely-regulated c-Myc expression in the heterogeneous CSC population in combination with the typical drug-repositioning with xCT inhibitor. BioMed Central 2017-02-13 /pmc/articles/PMC5307924/ /pubmed/28289330 http://dx.doi.org/10.1186/s12935-017-0393-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Hypothesis
Yoshida, Go J.
The heterogeneity of cancer stem-like cells at the invasive front
title The heterogeneity of cancer stem-like cells at the invasive front
title_full The heterogeneity of cancer stem-like cells at the invasive front
title_fullStr The heterogeneity of cancer stem-like cells at the invasive front
title_full_unstemmed The heterogeneity of cancer stem-like cells at the invasive front
title_short The heterogeneity of cancer stem-like cells at the invasive front
title_sort heterogeneity of cancer stem-like cells at the invasive front
topic Hypothesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307924/
https://www.ncbi.nlm.nih.gov/pubmed/28289330
http://dx.doi.org/10.1186/s12935-017-0393-y
work_keys_str_mv AT yoshidagoj theheterogeneityofcancerstemlikecellsattheinvasivefront
AT yoshidagoj heterogeneityofcancerstemlikecellsattheinvasivefront